BCL2L1 and melanoma: Increased expression of Bcl-X(L) has been described in various different malignancies including cancers of hematological origin such as acute myeloid leukemia and multiple myeloma but also in solid cancers like bladder cancer, breast cancer, pancreatic cancer and melanoma [10].